Loading patent…
AssigneeArray BioPharma Inc.
InventorsPatrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
Estimating the term…
Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
A method of treating a BRAF-associated tumor in a subject in need thereof, wherein said BRAF-associated tumor is a CNS tumor, wherein said method comprises administering a therapeutically effective amount of a compound of Formula III
A method of treating a BRAF-associated tumor in a subject in need thereof, wherein said BRAF-associated tumor is a CNS tumor, wherein said method comprises administering a therapeutically effective amount of a compound which is N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide having the structure
A method of treating a BRAF-associated tumor in a subject in need thereof, wherein said BRAF-associated tumor is a CNS tumor, wherein said method comprises administering a therapeutically effective amount of a compound which is N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide having the structure
A method of treating a BRAF-associated tumor in a subject in need thereof, wherein said BRAF-associated tumor is a CNS tumor, wherein said method comprises administering a therapeutically effective amount of a crystalline form of N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide Form B anhydrous.
Dependencies are inferred from the claim text.